Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The increase in both sales volume and unit prices, higher European B2C and European B2B sales at Towa Pharma International Holdings, S.L., and the offsetting of the deterioration in the performance of 三生医薬. The decrease in ordinary income was due to the derivative valuation loss of ¥2,355 million.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥142,254 million (YoY +9.0%) |
| Operating profit | ¥12,745 million (YoY +22.0%) |
| Ordinary income | ¥10,093 million (YoY -15.7%) |
| Profit attributable to owners of the parent | ¥6,866 million (YoY -16.4%) |
| Net income per share | ¥137.96 |
| Equity ratio | End of the current fiscal period 39.6% / End of previous period 37.5% |
| Total assets | ¥484,401 million |
| Net assets | ¥191,925 million |
| Cash flows from operating activities | ¥10,372 million |
| Cash flows from investing activities | ¥-7,087 million |
| Cash flows from financing activities | ¥10,686 million |
| Cash and cash equivalents at end of period | ¥59,581 million |
| Full-year earnings forecast | Net Sales ¥304,000 million (YoY +11.1%) / Operating profit ¥32,000 million (YoY +38.5%) / Ordinary income ¥30,000 million (YoY +6.8%) / Net income ¥21,500 million (YoY +309.5%) |
| Revision to Earnings Forecast | No change |
| Annual Dividend Forecast | ¥80 (common shares) → ¥85 (common shares) |
| Segment revenue | Japan ¥111,477 million (YoY +6.3%), Overseas ¥31,134 million (YoY +20.4%) |
| Segment profit | Japan ¥13,126 million (YoY -1.0%), Overseas ¥632 million |
| Depreciation and amortization | ¥9,341 million |
| Impairment loss | None (impairment losses on property, plant and equipment by reporting segment) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2 million / Extraordinary loss Loss on disposal of fixed assets ¥177 million |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 51,516,000 |
| Treasury Shares at Period-End | 2,286,945 |
| Factors Behind Changes in Business Performance | The increase in both sales volume and unit prices, higher European B2C and European B2B sales at Towa Pharma International Holdings, S.L., and the offsetting of the deterioration in the performance of 三生医薬. The decrease in ordinary income was due to the derivative valuation loss of ¥2,355 million. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in both sales volume and unit prices, together with higher European B2C and European B2B sales at Towa Pharma International Holdings, S.L., offset the deterioration in the performance of 三生医薬. The derivative valuation loss of ¥2,355 million was cited as the reason for the decreases in ordinary income and interim net income.